Startups
Developing differentiated treatment options For Patients with Autoimmune & Inflammatory Diseases About Us ValenzaBio is a privately-held biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. With a pipeline of differentiated monoclonal antibodies targeting clinically-validated mechanisms of action, we seek to provide improved therapies for patients with limited treatment options. Based in Bethesda, Maryland, in […]
Overview
Location
United States, Maryland, Bethesda
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 9, 2021 | ValenzaBio, Inc. announced that it has received $79.374978 million in funding from Fidelity Management & Research Company LLC, Citadel Advisors LLC, Ikarian Capital, LLC, Janus Henderson Group plc, Opaleye Management Inc. and other investors | On April 9, 2021, ValenzaBio, Inc. closed the transaction. The company has received $9,374,978 in its second tranche bringing the total funds raised in the transaction to $79,374,978. The transaction included participation from 13 investors... |
| Apr 8, 2021 | ValenzaBio picks up $70M, Pierre Fabre antibody for inflammatory eye disease | Maryland’s ValenzaBio reeled in a $70 million series A round that will propel a pair of monoclonal antibody programs toward the clinic. Those include a treatment for an autoimmune kidney disease, which is poised to start a phase 1b/2a study... |
Reviews 0
FAQ about ValenzaBio
What has the press written about ValenzaBio?
Parsers VC has collected 3 articles mentioning ValenzaBio, among them “ValenzaBio, Inc. announced that it has received $79.374978 million in funding from Fidelity Management & Research Company LLC, Citadel Advisors LLC, Ikarian ...” (Apr 9, 2021) and “ValenzaBio picks up $70M, Pierre Fabre antibody for inflammatory eye disease” (Apr 8, 2021).
Is ValenzaBio still active?
Yes, ValenzaBio is active; its latest activity on Parsers VC dates from Apr 21, 2021.